YMAB

Y mAbs Therapeutics Stock Price

41.80
1.00 (2.45%)
Upgrade to Real-Time
Regular Market
41.80
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Y mAbs Therapeutics Inc YMAB NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
1.00 2.45% 41.80 40.73 42.07 41.18 40.80 13:55:54
Bid Price Ask Price Spread Spread % News
41.75 41.87 0.12 0.29% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
793 30,697 $ 41.34 $ 1,269,127 216,885 14.16 - 50.49
Last Trade Time Type Quantity Stock Price Currency
13:55:53 68 $ 41.84 USD

Y mAbs Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.66B 39.76M 29.66M $ - $ - -2.31 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% -534.00k 1.10%

more financials information »

Y mAbs Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical YMAB Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week38.8742.0737.5539.25157,1892.937.54%
1 Month38.6642.3933.7138.40167,5563.148.12%
3 Months37.8850.4933.7141.99228,1793.9210.35%
6 Months34.1050.4914.1634.57232,2507.7022.58%
1 Year23.7850.4914.1632.49223,34118.0275.78%
3 Years26.5050.4914.1629.25179,72515.3057.74%
5 Years26.5050.4914.1629.25179,72515.3057.74%

Y mAbs Therapeutics Description

Y-mAbs Therapeutics Inc is a late-stage clinical biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Products developed by the company include naxitamab for the treatment of pediatric patients with relapsed or refractory and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system.


Your Recent History
NASDAQ
YMAB
Y mAbs The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.